Coya Therapeutics

COYA · NASDAQ

$4.21+$0.01 (+0.24%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.20

Latest news

Press releaseOct 14, 8:00 AM ETBusiness Wire
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Press releaseOct 13, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Press releaseOct 5, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Press releaseSep 15, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Press releaseSep 8, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
NewsJun 18, 8:11 AM ET
Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26
Press releaseJun 18, 8:00 AM ETBusiness Wire
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Press releaseJun 15, 8:00 AM ETBusiness Wire
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Press releaseJun 8, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Press releaseMay 27, 8:00 AM ETBusiness Wire
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Press releaseMay 12, 7:35 AM ETBusiness Wire
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Press releaseMay 12, 7:30 AM ETBusiness Wire
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Press releaseApr 9, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Press releaseApr 2, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Press releaseMar 24, 8:00 AM ETBusiness Wire
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
Press releaseMar 18, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Press releaseMar 16, 8:00 AM ETBusiness Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
NewsMar 12, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseFeb 10, 8:00 AM ETBusiness Wire
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Press releaseJan 30, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces $11.1 Million Private Placement
Press releaseJan 20, 8:00 AM ETBusiness Wire
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Press releaseJan 8, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Press releaseJan 5, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Press releaseDec 23, 8:00 AM ETBusiness Wire
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Press releaseDec 9, 8:00 AM ETBusiness Wire
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Press releaseNov 25, 8:00 AM ETBusiness Wire
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Press releaseNov 25, 8:00 AM ETBusiness Wire
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
NewsOct 23, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsAug 25, 5:07 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsAug 25, 9:57 AM ETHenry Khederian
What's Going On With Coya Therapeutics Stock?
NewsMay 1, 5:16 AM ETAvi Kapoor
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
NewsMar 14, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsFeb 6, 1:30 PM ETVandana Singh
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
NewsOct 29, 12:30 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

12 Health Care Stocks Moving In Thursday's After-Market Session

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics Announces $11.1 Million Private Placement

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

What's Going On With Coya Therapeutics Stock?

Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

12 Health Care Stocks Moving In Tuesday's Intraday Session